YMABのニュース
Y-mAbs Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA 2023/04/05 13:04:04 Investing.com
https://www.investing.com/news/assorted/ymabs-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-gd2sada-432SI-3049582
Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide 2023/03/31 18:30:47 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P 500, also rose, gaining, 0.79% to 4,082.66. Check This Out: Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street''s Most Accurate Analysts Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Friday. Meanwhile, top gainers in the sector included ContextLogic Inc. (NASDAQ: WISH ), up 13%, and Groupon, Inc. (NASDAQ: GRPN ), up 25%. In trading on Friday, utilities fell by 0.2%. Top Headline The personal consumption expenditure price index in rose by 5% year-over-year in February, the lowest since September 2021. The US core PCE price index, the Federal Reserve’s preferred inflation gauge, increased by 4.6% annually in February. Equities Trading UP Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) shares shot up 56% to $5.14 after the company posted a profit for the fourth quarter.
BCLI, SOUN and IPDN among mid-day movers 2023/03/31 16:58:15 Seeking Alpha
Gainers: Y-mAbs Therapeutics YMAB +61%.Burford Capital Limited BUR +42%.Pulse Biosciences PLSE +29%.Brainstorm Cell Therapeutics (BCLI) +29%.Bionomics Limited (BNOX)…
Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge 2023/03/31 16:02:12 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The S&P 500, also rose, gaining, 0.78% to 4,082.51. Check This Out: Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street''s Most Accurate Analysts Leading and Lagging Sectors Consumer discretionary shares jumped by 1.7% on Friday. Meanwhile, top gainers in the sector included Mullen Automotive, Inc. (NASDAQ: MULN ), up 14%, and Groupon, Inc. (NASDAQ: GRPN ), up 20%. In trading on Friday, utilities rose by just 0.2%. Top Headline The personal consumption expenditure price index in rose by 5% year-over-year in February, the lowest since September 2021. The US core PCE price index, the Federal Reserve’s preferred inflation gauge, increased by 4.6% annually in February. Equities Trading UP Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) shares shot up 76% to $5.80 after the company posted a profit for the fourth quarter.
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Call Transcript 2023/03/31 15:08:09 Seeking Alpha
Y-mAbs Therapeutics, Inc. (NASDAQ:NASDAQ:YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ETCompany ParticipantsThomas Gad - Founder, Interim CEO & PresidentSue Smith - SVP…
YMAB 2-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending 2023/03/06 21:01:00 GlobeNewswire
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options 2023/03/04 12:00:00 Benzinga
NEW YORK , March 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB ) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Y-mAbs stock or options between October 6, 2020 and October 28, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . You may also click here for additional information: www.faruqilaw.com/YMAB . There is no cost or obligation to you. Faruqi & Faruqi is a leading … Full story available on Benzinga.com
Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB 2023/03/04 03:50:00 Kwhen Finance
Y-mAbs Therapeutics: Omburtamab CRL Hits Hard, But All Is Not Over (NASDAQ:YMAB) 2023/03/02 05:59:11 Seeking Alpha
Y-mAbs Therapeutics will need to do a new trial for its neuroblastoma drug omburtamab to get approval. Read more to see my thoughts on YMAB stock.
YMAB SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed 2023/02/27 22:07:00 GlobeNewswire
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
Stocks to Watch: Neptune Wellness Solutions, Y-mAbs Therapeutics, Frequency Electronics 2022/12/16 23:17:00 MarketWatch
By Kathryn Hardison Neptune Wellness Solutions Inc. on Friday reported a wider loss for its fiscal second quarter. The consumer-packaged goods company''s…
Is Y-mAbs Therapeutics Inc. (YMAB) a opportunity to investors? 2022/12/13 14:40:00 US Post News
A share of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) closed at $4.88 per share on Monday, up from $4.36 day before. While Y-mAbs Therapeutics Inc. has overperformed by 11.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -70.13%, with highs and lows ranging from $20.48 […]
Do investors need to be concerned about Y-mAbs Therapeutics Inc. (YMAB)? 2022/12/06 16:00:00 US Post News
The share price of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) rose to $4.41 per share on Monday from $4.24. While Y-mAbs Therapeutics Inc. has overperformed by 4.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -73.03%, with highs and lows ranging from $20.48 to $2.94, […]
Y-mAbs neuroblastoma therapy rejected by FDA 2022/12/02 17:38:32 Seeking Alpha
Shares of Y-mAbs Therapeutics (YMAB) ended three days of back-to-back gains after the oncology-focused biotech announced that the FDA rejected its investigational therapy I-omburtamab…
How should investors view Y-mAbs Therapeutics Inc. (YMAB)? 2022/11/29 15:00:00 US Post News
Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) marked $4.18 per share on Monday, down from a previous closing price of $4.19. While Y-mAbs Therapeutics Inc. has underperformed by -0.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -75.63%, with highs and lows ranging from $20.48 to […]